Overview

Study to Assess Efficacy and Safety of Lanreotide Autogel 120 MG in Treatment of Clinical Symptoms Associated With Inoperable Malignant Intestinal Obstruction

Status:
Completed

Trial end date:
2017-11-09

Target enrollment:

Participant gender:

Summary

To assess the efficacy of Lanreotide Autogel 120 mg for the relief of vomiting due to inoperable malignant intestinal obstruction in patients without nasogastric tube (NGT) and to assess the efficacy of lanreotide Autogel 120 mg on removal of nasogastric tube without the recurrence of vomiting in patients with an inoperable malignant intestinal obstruction with a nasogastric tube.

Phase:

Phase 2

Details

Lead Sponsor:

Ipsen

Treatments:

Angiopeptin
Lanreotide
Somatostatin